TriSalus Life Sciences Receives FDA Clearance for TriNav Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery (PEDD) Portfolio for Liver Embolization
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the Company), an oncology company integrating novel delivery technology with standard-of-care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced it has received U.S. Food and Drug...